Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""HEPATITIS B"" wg kryterium: Temat


Tytuł:
Long-Term Outcomes after Switching to Tenofovir Alafenamide in Patients with Chronic Hepatitis B.
Autorzy:
Nishikawa T; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Matsui M; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Onishi S; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Ushiro K; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Asai A; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Kim SK; Department of Gastroenterology, Kobe Asahi Hospital, Kobe 653-8501, Japan.
Nishikawa H; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki 569-8686, Japan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Feb 13; Vol. 25 (4). Date of Electronic Publication: 2024 Feb 13.
Typ publikacji:
Journal Article
MeSH Terms:
Antiviral Agents*/adverse effects
Hepatitis B, Chronic*/drug therapy
Humans ; Middle Aged ; Tenofovir/adverse effects ; Hepatitis B Surface Antigens ; Hepatitis B e Antigens ; DNA, Viral ; Alanine/therapeutic use ; Adenine/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Cost-effectiveness of tenofovir alafenamide and entecavir in chronic hepatitis B in Saudi Arabia.
Autorzy:
Al-Jedai A; Assistant Deputy Minister for Medical Support Services, Riyadh, Saudi Arabia.; Deputyship of Therapeutic Affairs, Ministry of Health, Riyadh, Saudi Arabia.; Professor, Colleges of Medicine and Pharmacy, Alfaisal University, Riyadh, Saudi Arabia.; Consultant Clinical Pharmacist, Solid Organ Transplant, Riyadh, Saudi Arabia.
Pokaż więcej
Źródło:
Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association [Saudi J Gastroenterol] 2024 Jan 01; Vol. 30 (1), pp. 1-3. Date of Electronic Publication: 2024 Jan 08.
Typ publikacji:
Journal Article
MeSH Terms:
Hepatitis B, Chronic*/drug therapy
Hepatitis B, Chronic*/epidemiology
Tenofovir*/analogs & derivatives
Tenofovir*/therapeutic use
Antiviral Agents*/therapeutic use
Humans ; Cost-Benefit Analysis ; Saudi Arabia/epidemiology ; Alanine/therapeutic use ; Guanine/analogs & derivatives ; Guanine/therapeutic use
Czasopismo naukowe
Tytuł:
Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals.
Autorzy:
Hwang SY; Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea.
Yoo SH; Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea.
Chang HY; Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea.
Kim S; Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea.
Lee JI; Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea.
Lee KS; Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea.
Cho YY; Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Joon KH; Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Lee HW; Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, Korea.
Pokaż więcej
Źródło:
Journal of viral hepatitis [J Viral Hepat] 2023 Jan; Vol. 30 (1), pp. 39-45. Date of Electronic Publication: 2022 Nov 11.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents*/therapeutic use
Hepatitis B, Chronic*
Humans ; Hepatitis B e Antigens ; Hepatitis B Core Antigens ; Hepatitis B Surface Antigens ; Retrospective Studies ; DNA, Viral/analysis ; Hepatitis B virus/genetics ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial.
Autorzy:
Jia H; Phase I Clinical Research Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun, Jilin Province, China.; Gynecology and Obstetrics Center, the First Hospital of Jilin University, Changchun, China.
Mai J; Phase I Clinical Research Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun, Jilin Province, China.
Wu M; Phase I Clinical Research Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun, Jilin Province, China.
Chen H; Phase I Clinical Research Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun, Jilin Province, China.
Li X; Phase I Clinical Research Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun, Jilin Province, China.
Li C; Phase I Clinical Research Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun, Jilin Province, China.
Liu J; Phase I Clinical Research Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun, Jilin Province, China.
Liu C; Phase I Clinical Research Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun, Jilin Province, China.
Hu Y; Phase I Clinical Research Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun, Jilin Province, China.
Zhu X; Phase I Clinical Research Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun, Jilin Province, China.
Jiang X; Shanghai Zhimeng Biopharma, Inc, 1976 Gaoke Middle Road, Suite A-302, Pudong District, Shanghai, China.
Hua B; Shanghai Zhimeng Biopharma, Inc, 1976 Gaoke Middle Road, Suite A-302, Pudong District, Shanghai, China.
Xia T; Shanghai Zhimeng Biopharma, Inc, 1976 Gaoke Middle Road, Suite A-302, Pudong District, Shanghai, China.
Liu G; Shanghai Zhimeng Biopharma, Inc, 1976 Gaoke Middle Road, Suite A-302, Pudong District, Shanghai, China.
Deng A; Shanghai Zhimeng Biopharma, Inc, 1976 Gaoke Middle Road, Suite A-302, Pudong District, Shanghai, China.
Liang B; Shanghai Zhimeng Biopharma, Inc, 1976 Gaoke Middle Road, Suite A-302, Pudong District, Shanghai, China.
Guo R; Shanghai Zhimeng Biopharma, Inc, 1976 Gaoke Middle Road, Suite A-302, Pudong District, Shanghai, China.
Lu H; Shanghai Zhimeng Biopharma, Inc, 1976 Gaoke Middle Road, Suite A-302, Pudong District, Shanghai, China.
Wang Z; Shanghai Zhimeng Biopharma, Inc, 1976 Gaoke Middle Road, Suite A-302, Pudong District, Shanghai, China.
Chen H; Shanghai Zhimeng Biopharma, Inc, 1976 Gaoke Middle Road, Suite A-302, Pudong District, Shanghai, China.
Zhang Z; Shanghai Zhimeng Biopharma, Inc, 1976 Gaoke Middle Road, Suite A-302, Pudong District, Shanghai, China.
Zhang H; Phase I Clinical Research Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun, Jilin Province, China. .
Niu J; Department of Hepatology, Center of Infectious Disease and Pathogen Biology, The First Hospital of Jilin University, Changchun, China. .
Ding Y; Phase I Clinical Research Center, The First Hospital of Jilin University, No. 1 Xinmin Street, Changchun, Jilin Province, China. .
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2023 Mar 16; Vol. 21 (1), pp. 98. Date of Electronic Publication: 2023 Mar 16.
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents*/adverse effects
Hepatitis B, Chronic*/drug therapy
Humans ; DNA, Viral/therapeutic use ; Hepatitis B virus ; Double-Blind Method
Czasopismo naukowe
Tytuł:
Safety, pharmacokinetics and antiviral activity of ABI-H2158, a hepatitis B virus core inhibitor: A randomized, placebo-controlled phase 1 study.
Autorzy:
Agarwal K; Institute of Liver Studies, King's College Hospital, London, UK.
Xu J; Phase 1 Clinical Trials Unit, The First Hospital of Jilin University, Jilin, China.
Gane EJ; University of Auckland, Auckland, New Zealand.
Nguyen TT; T Nguyen Research and Education, Inc., San Diego, California, USA.
Ding Y; Phase 1 Clinical Trials Unit, The First Hospital of Jilin University, Jilin, China.
Knox SJ; Assembly Biosciences, Inc., South San Francisco, California, USA.
Alves K; Assembly Biosciences, Inc., South San Francisco, California, USA.
Evanchik M; Assembly Biosciences, Inc., South San Francisco, California, USA.
Zomorodi K; Assembly Biosciences, Inc., South San Francisco, California, USA.
Ma J; Assembly Biosciences, Inc., South San Francisco, California, USA.
Yan R; Assembly Biosciences, Inc., South San Francisco, California, USA.
Huang Q; Assembly Biosciences, Inc., South San Francisco, California, USA.
Colonno R; Assembly Biosciences, Inc., South San Francisco, California, USA.
Stamm LM; Assembly Biosciences, Inc., South San Francisco, California, USA.
Hassanein TI; Southern California Research Center, Coronado, California, USA.
Kim DJ; Hallym University Chuncheon Sacred Heart Hospital, Chuncheon, South Korea.
Lim YS; Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea.
Yuen MF; Department of Medicine, University of Hong Kong, Hong Kong, Hong Kong.
Pokaż więcej
Źródło:
Journal of viral hepatitis [J Viral Hepat] 2023 Mar; Vol. 30 (3), pp. 209-222. Date of Electronic Publication: 2023 Jan 12.
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents*/therapeutic use
Hepatitis B, Chronic*/drug therapy
Humans ; Hepatitis B virus ; Double-Blind Method ; Dose-Response Relationship, Drug
Czasopismo naukowe
Tytuł:
Primary non-response to antiviral therapy affects the prognosis of hepatitis B virus-related hepatocellular carcinoma.
Autorzy:
Wang P; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Beijing, 100015, P.R. China.
Wang X; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Beijing, 100015, P.R. China.
Liu X; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Beijing, 100015, P.R. China.
Yan F; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Beijing, 100015, P.R. China.
Yan H; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Beijing, 100015, P.R. China.
Zhou D; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Beijing, 100015, P.R. China.
Yu L; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Beijing, 100015, P.R. China.
Wang X; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Beijing, 100015, P.R. China.
Yang Z; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, No. 8 Jing Shun East Street, Beijing, 100015, P.R. China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Jun 20; Vol. 23 (1), pp. 564. Date of Electronic Publication: 2023 Jun 20.
Typ publikacji:
Journal Article
MeSH Terms:
Antiviral Agents*/therapeutic use
Hepatitis B*/complications
Hepatitis B*/drug therapy
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/virology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/virology
Humans ; Prognosis ; Survival Rate ; Retrospective Studies ; China ; DNA, Viral/blood ; Male ; Female ; Middle Aged ; Aged
Czasopismo naukowe
Tytuł:
Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B.
Autorzy:
Hsu PK; Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
Su PY; Division of Gastroenterology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.
Wu CL; School of Medicine, Chung Shan Medical University, Taichung, Taiwan. .; Division of Nephrology, Changhua Christian Hospital, Changhua, Taiwan. .; School of Medicine, National Chung Hsing University, Taichung, Taiwan. .
Pokaż więcej
Źródło:
BMC gastroenterology [BMC Gastroenterol] 2022 May 10; Vol. 22 (1), pp. 228. Date of Electronic Publication: 2022 May 10.
Typ publikacji:
Journal Article; Retracted Publication
MeSH Terms:
Antiviral Agents*/adverse effects
Hepatitis B, Chronic*
DNA, Viral ; Drugs, Generic/adverse effects ; Guanine/analogs & derivatives ; Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Humans ; Retrospective Studies ; Treatment Outcome ; Viral Load
Czasopismo naukowe
Tytuł:
Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure.
Autorzy:
Vaillant A; Replicor Inc., 6100 Royalmount Avenue, Montreal, QC H4P 2R2, Canada.
Pokaż więcej
Źródło:
Viruses [Viruses] 2021 Apr 23; Vol. 13 (5). Date of Electronic Publication: 2021 Apr 23.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Hepatitis B virus*/drug effects
Alanine Transaminase/*blood
Antiviral Agents/*therapeutic use
Hepatitis B, Chronic/*blood
Hepatitis B, Chronic/*drug therapy
Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Biomarkers ; Disease Susceptibility ; Hepatitis B Surface Antigens/blood ; Hepatitis B e Antigens/blood ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/virology ; Hepatocytes/metabolism ; Hepatocytes/pathology ; Hepatocytes/virology ; Humans ; Liver Function Tests
Czasopismo naukowe
Tytuł:
HBV cure-The light at the end of the tunnel?
Autorzy:
Sandmann L; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Maasoumy B; Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
Pokaż więcej
Źródło:
Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2023 Mar; Vol. 43 (3), pp. 531-533.
Typ publikacji:
Editorial; Research Support, Non-U.S. Gov't
MeSH Terms:
Hepatitis B virus*
Antiviral Agents*
Humans ; Virus Replication
Raport
Tytuł:
Sequence characterization of extracellular HBV RNA in patient plasma.
Autorzy:
Chang S; Gilead Sciences, Inc., Foster City, California, USA.
Hedskog C; Gilead Sciences, Inc., Foster City, California, USA.
Parhy B; Gilead Sciences, Inc., Foster City, California, USA.
Martin R; Gilead Sciences, Inc., Foster City, California, USA.
Mo H; Gilead Sciences, Inc., Foster City, California, USA.
Maiorova E; Gilead Sciences, Inc., Foster City, California, USA.
Zoulim F; INSERM U1052, CNRS UMR-5286, Cancer Research Center of Lyon (CRCL), Lyon, France.; University of Lyon, Université Claude-Bernard (UCBL), Lyon, France.; Hospices Civils de Lyon (HCL), Lyon, France.
Pokaż więcej
Źródło:
Journal of viral hepatitis [J Viral Hepat] 2023 Jan; Vol. 30 (1), pp. 29-38. Date of Electronic Publication: 2022 Oct 17.
Typ publikacji:
Journal Article
MeSH Terms:
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
Hepatitis B virus*/genetics
Humans ; Biomarkers ; DNA, Viral ; RNA, Viral ; Virus Replication ; Subgenomic RNA
Czasopismo naukowe
Tytuł:
Functional cure for chronic hepatitis B: accessibility, durability, and prognosis.
Autorzy:
Song A; First Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Lin X; First Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Chen X; First Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing, China. .
Pokaż więcej
Źródło:
Virology journal [Virol J] 2021 Jun 03; Vol. 18 (1), pp. 114. Date of Electronic Publication: 2021 Jun 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Antiviral Agents*/therapeutic use
Hepatitis B, Chronic*/diagnosis
Hepatitis B, Chronic*/drug therapy
Hepatitis B Surface Antigens ; Hepatitis B e Antigens ; Hepatitis B virus ; Humans ; Prognosis ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Ribavirin Does Not Enhance Hepatitis B Virus Nucleotide Antiviral Activity: A Pilot Study.
Autorzy:
Keeshan A; School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada. .
Coffin C; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. .
Vachon A; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada. .
Patel N; Cumming School of Medicine, University of Calgary, Calgary, AB, Canada . .
Fung S; Toronto General Hospital, Toronto, Ontario, Canada. .
Mortimer L; Eastern Ontario Regional Laboratory Association, ON, Canada. .
Crawley A; Ottawa Hospital Research Institute, Ottawa, ON, Canada. .
Ma M; Department of Medicine, University of Alberta, Edmonton, AB, Canada. .
Osiowy C; Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB, Canada; National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada. .
Cooper C; School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON, Canada; Ottawa Hospital Research Institute, Ottawa, ON, Canada. .
Pokaż więcej
Źródło:
Clinical and investigative medicine. Medecine clinique et experimentale [Clin Invest Med] 2022 Dec 31; Vol. 45 (4), pp. E11-15. Date of Electronic Publication: 2022 Dec 31.
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents*/pharmacology
Antiviral Agents*/therapeutic use
Hepatitis B virus*
Ribavirin/therapeutic use ; Ribavirin/pharmacology ; Pilot Projects ; Nucleotides/pharmacology ; Treatment Outcome ; Drug Therapy, Combination ; Tenofovir/therapeutic use ; Tenofovir/adverse effects
Czasopismo naukowe
Tytuł:
Cost-Effectiveness of Hepatitis B Mass Screening and Management in High-Prevalent Rural China: A Model Study From 2020 to 2049.
Autorzy:
Xu X; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Wu C; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Jiang L; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Peng C; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Pan L; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Zhang X; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Shen W; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Chen L; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Lou Z; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Xu K; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Li L; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Dong Y; People's Hospital Medical Community of Yuhuan County, Taizhou, China.
Ruan B; State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Pokaż więcej
Źródło:
International journal of health policy and management [Int J Health Policy Manag] 2022 Oct 19; Vol. 11 (10), pp. 2115-2123. Date of Electronic Publication: 2021 Sep 07.
Typ publikacji:
Journal Article
MeSH Terms:
Antiviral Agents*/therapeutic use
Hepatitis B, Chronic*/diagnosis
Hepatitis B, Chronic*/epidemiology
Hepatitis B, Chronic*/prevention & control
Adult ; Humans ; Cost-Benefit Analysis ; Prevalence ; Mass Screening ; China/epidemiology
Czasopismo naukowe
Tytuł:
Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B.
Autorzy:
Nagura Y; Departments of Virology & Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.; Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Matsuura K; Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Iio E; Departments of Virology & Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Fujita K; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki, Kagawa, Japan.
Inoue T; Department of Clinical Laboratory Medicine, Nagoya City University Hospital, Nagoya, Aichi, Japan.
Matsumoto A; Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Nagano, Japan.
Tanaka E; Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Nagano, Japan.
Nishiguchi S; Division of Hepatobiliary and Pancreatic Disease, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Hyogo, Japan.
Kang JH; Division of Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Hokkaido, Japan.
Matsui T; Division of Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Hokkaido, Japan.
Enomoto M; Department of Hepatology, Graduate School of Medicine, Osaka City University, Osaka, Osaka, Japan.
Ikeda H; Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Watanabe T; Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
Okuse C; Division of General Internal Medicine, Department of Internal Medicine, Kawasaki Municipal Tama Hospital, Kawasaki, Kanagawa, Japan.
Tsuge M; Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima, Japan.
Atsukawa M; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Tateyama M; Department of Gastroenterology and Hepatology Faculty of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.
Kataoka H; Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Tanaka Y; Departments of Virology & Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.; Department of Gastroenterology and Hepatology Faculty of Life Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2022 Feb 14; Vol. 17 (2), pp. e0263844. Date of Electronic Publication: 2022 Feb 14 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents/*therapeutic use
Hepatitis B, Chronic/*drug therapy
Interferon-alpha/*therapeutic use
MicroRNAs/*blood
Polyethylene Glycols/*therapeutic use
Adult ; Antiviral Agents/pharmacology ; Biomarkers/blood ; Case-Control Studies ; DNA, Viral/drug effects ; DNA, Viral/genetics ; Female ; Gene Expression Regulation/drug effects ; Hepatitis B virus/drug effects ; Hepatitis B virus/genetics ; Hepatitis B, Chronic/genetics ; Hepatitis B, Chronic/virology ; Humans ; Male ; Middle Aged ; Recombinant Proteins/therapeutic use ; Regression Analysis ; Treatment Outcome ; Viral Load/drug effects
Czasopismo naukowe
Tytuł:
Bay41-4109-induced aberrant polymers of hepatitis b capsid proteins are removed via STUB1-promoted p62-mediated macroautophagy.
Autorzy:
Lin J; Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou, China.; Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, China.
Yin L; Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou, China.
Xu XZ; Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou, China.
Sun HC; Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou, China.
Huang ZH; Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou, China.
Ni XY; Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou, China.
Chen Y; Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou, China.; Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, China.
Lin X; Key Laboratory of Gastrointestinal Cancer (Fujian Medical University), Ministry of Education, Fuzhou, China.; Fujian Key Laboratory of Tumor Microbiology, Department of Medical Microbiology, Fujian Medical University, Fuzhou, China.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2022 Jan 14; Vol. 18 (1), pp. e1010204. Date of Electronic Publication: 2022 Jan 14 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents/*pharmacology
Capsid Proteins/*drug effects
Hepatitis B virus/*drug effects
Hepatitis B virus/*metabolism
Ubiquitin-Protein Ligases/*metabolism
Animals ; Capsid Proteins/metabolism ; Hepatitis B/virology ; Humans ; Macroautophagy/drug effects ; Mice
Czasopismo naukowe
Tytuł:
Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg).
Autorzy:
Lim SG; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Phyo WW; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.
Ling JZJ; Singapore Clinical Research Institute, Singapore.
Cloherty G; Abbott Laboratories, Abbott Park, IL, USA.
Butler EK; Abbott Laboratories, Abbott Park, IL, USA.
Kuhns MC; Abbott Laboratories, Abbott Park, IL, USA.
McNamara AL; Abbott Laboratories, Abbott Park, IL, USA.
Holzmayer V; Abbott Laboratories, Abbott Park, IL, USA.
Gersch J; Abbott Laboratories, Abbott Park, IL, USA.
Yang WL; Tan Tock Seng Hospital, Singapore.
Ngu JH; Singapore General Hospital, Singapore.
Chang J; Singapore General Hospital, Singapore.
Tan J; Changi General Hospital, Singapore.
Ahmed T; Khoo Teck Puat Hospital, Singapore.
Dan YY; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Lee YM; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Lee GH; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Tan PS; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.
Huang DQ; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.; Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Khine HTW; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.
Lee C; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.
Tay A; Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.
Chan E; Singapore Clinical Research Institute, Singapore.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Jan; Vol. 53 (1), pp. 172-182. Date of Electronic Publication: 2020 Nov 07.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents*/therapeutic use
Hepatitis B, Chronic*/diagnosis
Hepatitis B, Chronic*/drug therapy
Biomarkers ; DNA, Viral ; Hepatitis B Surface Antigens ; Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Humans
Czasopismo naukowe
Tytuł:
Uptake of hepatitis B antiviral treatment: A panel data analysis of 31 provinces in China (2013-2020).
Autorzy:
Cheng H; School of Health Policy and Management, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
Liu S; Medical School of Chinese PLA/The Fifth Medical Center of PLA General Hospital, Beijing, P. R. China.
Luo S; IQVIA Holding Company, Beijing, P. R. China.
Chan P; Hepatitis|TB|HIV|STI, World Health Organisation Regional Office for the Western Pacific, Manila, Philippines.
Chen Z; Hepatitis|TB|HIV|STI, World Health Organization Representative Office in China, Beijing, P. R. China.
Le LV; Hepatitis|TB|HIV|STI, World Health Organisation Regional Office for the Western Pacific, Manila, Philippines.
Sun J; School of Health Policy and Management, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
Pokaż więcej
Źródło:
Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2022 Aug; Vol. 42 (8), pp. 1762-1769. Date of Electronic Publication: 2022 Jun 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents*/therapeutic use
Hepatitis B*/drug therapy
Hepatitis B*/epidemiology
China/epidemiology ; Data Analysis ; Humans
Czasopismo naukowe
Tytuł:
Randomised clinical trial: safety, efficacy and pharmacokinetics of HS-10234 versus tenofovir for the treatment of chronic hepatitis B infection.
Autorzy:
Zhang H; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Hu Y; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Wu M; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Liu J; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Zhu X; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Li X; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Chen H; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Li C; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Liu C; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Niu J; Department of Hepatology, The First Hospital of Jilin University, Jilin, China.
Ding Y; Phase I Clinical Research Center, The First Hospital of Jilin University, Jilin, China.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Jan; Vol. 53 (2), pp. 243-252. Date of Electronic Publication: 2020 Nov 28.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents*/adverse effects
Hepatitis B, Chronic*/drug therapy
DNA, Viral ; Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Humans ; Leukocytes, Mononuclear ; Tenofovir/adverse effects ; Treatment Outcome ; Viral Load
Czasopismo naukowe
Tytuł:
Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss.
Autorzy:
Brakenhoff SM; Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
de Man RA; Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Boonstra A; Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
van Campenhout MJH; Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
de Knegt RJ; Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
van Bömmel F; Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
van der Eijk AA; Department of Viroscience, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Berg T; Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
Hansen BE; Toronto Center for Liver Disease, Toronto Western and General Hospital, University Health Network, Toronto, ON, Canada.; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada.
Janssen HLA; Toronto Center for Liver Disease, Toronto Western and General Hospital, University Health Network, Toronto, ON, Canada.
Sonneveld MJ; Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Jan; Vol. 53 (2), pp. 314-320. Date of Electronic Publication: 2020 Nov 21.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents*/therapeutic use
Hepatitis B, Chronic*/drug therapy
Antigens, Viral/therapeutic use ; DNA, Viral ; Hepatitis B Surface Antigens ; Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Humans ; Probability ; RNA/therapeutic use ; Randomized Controlled Trials as Topic ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogue-induced hepatitis B surface antigen loss.
Autorzy:
Yip TC; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.; Medical Data Analytic Centre (MDAC), The Chinese University of Hong Kong, Hong Kong SAR, China.; Institute of Digestive Disease, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Wong VW; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.; Medical Data Analytic Centre (MDAC), The Chinese University of Hong Kong, Hong Kong SAR, China.; Institute of Digestive Disease, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Tse YK; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.; Medical Data Analytic Centre (MDAC), The Chinese University of Hong Kong, Hong Kong SAR, China.; Institute of Digestive Disease, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Liang LY; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Hui VW; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Zhang X; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Li GL; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Lui GC; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.; Medical Data Analytic Centre (MDAC), The Chinese University of Hong Kong, Hong Kong SAR, China.
Chan HL; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.; Medical Data Analytic Centre (MDAC), The Chinese University of Hong Kong, Hong Kong SAR, China.; Institute of Digestive Disease, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Wong GL; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.; Medical Data Analytic Centre (MDAC), The Chinese University of Hong Kong, Hong Kong SAR, China.; Institute of Digestive Disease, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
Pokaż więcej
Źródło:
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2021 Jan; Vol. 53 (2), pp. 321-331. Date of Electronic Publication: 2020 Nov 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antiviral Agents*/adverse effects
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/epidemiology
Carcinoma, Hepatocellular*/etiology
Hepatitis B, Chronic*/complications
Hepatitis B, Chronic*/drug therapy
Liver Neoplasms*/drug therapy
Liver Neoplasms*/epidemiology
Liver Neoplasms*/etiology
Adult ; Aged ; DNA, Viral ; Hepatitis B Surface Antigens ; Hong Kong/epidemiology ; Humans ; Male ; Middle Aged
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies